Brepocitinib Overview & RVT-3101 Update
RVT-3101
VTAMA! Psoriasis | Dermavant
(tapinarof) cream 1%
✓✓ Atopic Dermatitis | Dermavant
VTAMA
(tapinarof) cream 1%
RVT-3101 Ulcerative Colitis | New Vant
RVT-3101 Crohn's Diseases | New Vant
BREPOCITINIB Dermatomyositis | Priovant
BREPOCITINIB Systemic Lupus Erythematosus | Priovant
BREPOCITINIB Other Indications | Priovant
Y BATOCLIMAB Myasthenia Gravis | Immunovant
Modality
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Topical
Topical
Biologic
Biologic
Small Molecule
Small Molecule
Small Molecule
Biologic
Biologic
BATOCLIMAB Thyroid Eye Disease | Immunovant
BATOCLIMAB Chronic Inflammatory Demyelinating Polyneuropathy | Immunovant
Biologic
др
BATOCLIMAB Graves' Disease | Immunovant
Biologic
Y
BATOCLIMAB Warm Autoimmune Hemolytic Anemia | Immunovant
Biologic
IMVT-1402 Numerous Indications | Immunovant
Biologic
n
NAMILUMAB Sarcoidosis | Kinevant
Biologic
RVT-2001 Transfusion-Dependent Anemia in Patients with Lower-Risk MDS | Hemavant
roivant
Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis.
Small Molecule
A
A
A
A
A
Represents registrational or potentially
registrational trials
For investor audiences only
7View entire presentation